Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MATTHEW BUDOFF

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1811967433
CMS profile
127894
Location
TORRANCE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$407,315.94

383 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 8; records 101–150 of 383 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MATTHEW BUDOFF

NPI 1811967433 · CMS profile ID 127894

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

TORRANCE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 8; records 101–150 of 383 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1811967433?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MATTHEW BUDOFF, NPI 1811967433, CMS profile ID 127894. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 8; records 101–150 of 383 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1811967433?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). MATTHEW BUDOFF, NPI 1811967433, CMS profile ID 127894. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 8; records 101–150 of 383 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1811967433?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
MATTHEW BUDOFF, NPI 1811967433, CMS profile ID 127894, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 8; records 101–150 of 383 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1811967433?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

383 matching records · $407,315.94 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 383 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 383.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $25.5109/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048878573 CMS
Merck Sharp & Dohme LLC $478.4309/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048911203 CMS
Regeneron Healthcare Solutions, Inc. $5,728.0009/14/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999107667 CMS
Regeneron Healthcare Solutions, Inc. $170.6509/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999107663 CMS
Merck Sharp & Dohme LLC $150.0009/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048491131 CMS
Regeneron Healthcare Solutions, Inc. $15.0009/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999107651 CMS
Regeneron Healthcare Solutions, Inc. $31.4409/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999107655 CMS
Regeneron Healthcare Solutions, Inc. $27.5109/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999107659 CMS
Merck Sharp & Dohme LLC $727.4009/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048490725 CMS
Merck Sharp & Dohme LLC $26.0309/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048491289 CMS
Merck Sharp & Dohme LLC $529.8009/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048876133 CMS
Regeneron Healthcare Solutions, Inc. $63.9909/09/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999107647 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $463.0509/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993424419 CMS
Novartis Pharmaceuticals Corporation $7,400.0009/07/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993424435 CMS
Novartis Pharmaceuticals Corporation $130.3209/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993424437 CMS
Novartis Pharmaceuticals Corporation $424.3909/07/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993424441 CMS
Novartis Pharmaceuticals Corporation $572.5009/07/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993424443 CMS
Novartis Pharmaceuticals Corporation $111.9909/07/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993424445 CMS
Novartis Pharmaceuticals Corporation $344.4809/07/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993424447 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $492.4509/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993424417 CMS
Regeneron Healthcare Solutions, Inc. $4,296.0009/05/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999107643 CMS
Amgen Inc. $10.4809/04/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020019123 CMS
Amgen Inc. $2,800.0009/04/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020019131 CMS
Amgen Inc. $125.0008/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020019117 CMS
Regeneron Healthcare Solutions, Inc. $27.7008/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999107639 CMS
Amgen Inc. $180.7808/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020019103 CMS
Amgen Inc. $2,800.0008/28/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020019105 CMS
Amgen Inc. $467.0008/28/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020019107 CMS
Amgen Inc. $36.6108/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020019109 CMS
Amgen Inc. $13.9008/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020019111 CMS
Regeneron Healthcare Solutions, Inc. $340.8108/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999107635 CMS
Amgen Inc. $121.8408/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020019101 CMS
Lilly USA, LLC $1,800.0008/23/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031890807 CMS
Janssen Pharmaceuticals, Inc $1,200.0008/18/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988580011 CMS
Lexicon Pharmaceuticals, Inc. $415.5408/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040799365 CMS
Amgen Inc. $2,800.0008/03/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020019093 CMS
Amgen Inc. $467.0008/03/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020019095 CMS
Regeneron Healthcare Solutions, Inc. $4,296.0008/03/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999107631 CMS
Amgen Inc. $163.7508/02/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020019089 CMS
Amgen Inc. $16.0008/02/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020019091 CMS
Janssen Pharmaceuticals, Inc $1,200.0008/02/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988580007 CMS
Amgen Inc. $120.8907/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020019087 CMS
Regeneron Healthcare Solutions, Inc. $38.2307/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999107627 CMS
Amgen Inc. $5.5207/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020019085 CMS
AstraZeneca Pharmaceuticals LP $4,300.0007/25/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011568455 CMS
Lexicon Pharmaceuticals, Inc. $23.0707/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040731439 CMS
Novartis Pharmaceuticals Corporation $38.7307/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991437215 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $1,200.0007/19/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996551725 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $1,200.0007/19/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997120865 CMS
Merck Sharp & Dohme LLC $1,635.0007/19/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048569741 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $640,390.46 660
PY2020 $407,996.72 367
PY2021 $558,227.34 432
PY2022 $487,475.55 435
PY2023 $407,315.94 383
PY2024 $574,074.03 406
PY2025 $541,709.23 454

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $19,093.06 9
PY2025 Principal investigator $1,159,945.76 40
PY2024 Recipient $474,548.50 3
PY2024 Principal investigator $876,843.21 71
PY2023 Recipient $65,346.50 3
PY2023 Principal investigator $910,851.85 113
PY2022 Recipient $1,794.49 8
PY2022 Principal investigator $783,031.83 111
PY2021 Recipient $940.00 1
PY2021 Principal investigator $1,077,613.94 313
PY2020 Recipient $21,712.08 10
PY2020 Principal investigator $1,440,514.07 410
PY2019 Principal investigator $1,441,179.18 581

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

49 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $9,108.34 12/31/2025 Non-covered Recipient Entity
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction No dispute reported 06/30/2026 1232920281
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $200.00 12/23/2025 Non-covered Recipient Entity
Lundquist Inst For Biomed At Harbor-ucla Medical
A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LV No dispute reported 06/30/2026 1225415010
Recipient Cleerly, Inc. $750.00 12/05/2025 Covered Recipient Physician TRANSFORM No dispute reported 06/30/2026 1241147830
Principal investigator 1 AstraZeneca Pharmaceuticals LP $19,100.00 12/03/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR UCLA
A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event No dispute reported 06/30/2026 1185552741
Principal investigator 1 AstraZeneca Pharmaceuticals LP $36,900.00 11/30/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR UCLA
Randomized Double blind Placebo controlled Parallel Group Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD No dispute reported 06/30/2026 1185552743
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,000.00 11/30/2025 Non-covered Recipient Entity
LAYOUS MEDICAL GROUP
Randomized Double blind Placebo controlled Parallel Group Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD No dispute reported 06/30/2026 1185552747
Principal investigator 1 Cleerly, Inc. $1,345.00 11/26/2025 Non-covered Recipient Entity
The Lunquist Institute
Confirm2 No dispute reported 06/30/2026 1241147496
Principal investigator 1 Novo Nordisk AS $1,333.32 10/31/2025 Non-covered Recipient Entity
THE LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION
NN9535-4321 No dispute reported 06/30/2026 1213747164
Recipient Novartis Pharma AG $284.36 10/29/2025 Covered Recipient Physician CKJX839D12303 No dispute reported 06/30/2026 1248109417
Recipient Novartis Pharma AG $484.08 10/29/2025 Covered Recipient Physician CKJX839D12303 No dispute reported 06/30/2026 1248109419
Recipient Novartis Pharma AG $188.35 10/29/2025 Covered Recipient Physician CKJX839D12303 No dispute reported 06/30/2026 1248109421
Recipient Novartis Pharma AG $184.27 10/29/2025 Covered Recipient Physician CKJX839D12303 No dispute reported 06/30/2026 1248109423
Principal investigator 1 Novartis Pharmaceuticals Corporation $203.67 10/27/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA AT LOS ANGELES
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190302351
Principal investigator 1 Ionis Pharmaceuticals, Inc. $100.00 10/21/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
IS354CS9 No dispute reported 06/30/2026 1246789500
Principal investigator 1 Ionis Pharmaceuticals, Inc. $9,100.00 10/16/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
IS354CS9 No dispute reported 06/30/2026 1246789371
Principal investigator 1 GE HEALTHCARE $91,518.11 10/15/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
20HC-G-Cardiac CT Deblooming No dispute reported 06/30/2026 1244366631
Principal investigator 1 GE HEALTHCARE $83,182.54 10/08/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
20HC-G-Cardiac CT Deblooming No dispute reported 06/30/2026 1244366627
Principal investigator 1 GE HEALTHCARE $140,180.56 10/08/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
20HC-G-Cardiac CT Deblooming No dispute reported 06/30/2026 1244366629
Principal investigator 1 Ionis Pharmaceuticals, Inc. $650.00 10/08/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
IS354CS9 No dispute reported 06/30/2026 1246788352
Principal investigator 1 Ionis Pharmaceuticals, Inc. $675.00 10/08/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
IS354CS9 No dispute reported 06/30/2026 1246788356
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,000.00 10/08/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
IS354CS9 No dispute reported 06/30/2026 1246788359
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,275.00 10/08/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
IS354CS9 No dispute reported 06/30/2026 1246788363
Principal investigator 1 Ionis Pharmaceuticals, Inc. $2,380.00 10/08/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
IS354CS9 No dispute reported 06/30/2026 1246788368
Principal investigator 1 Ionis Pharmaceuticals, Inc. $13,770.39 10/08/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
IS354CS9 No dispute reported 06/30/2026 1246788371
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,836.61 09/02/2025 Non-covered Recipient Entity
HARBOR - UCLA MEDICAL CENTER
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190301467
Recipient Novartis Pharma AG $92.55 08/29/2025 Covered Recipient Physician CKJX839D12303 No dispute reported 06/30/2026 1248109839
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,300.00 08/22/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR UCLA
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure No dispute reported 06/30/2026 1185552737
Principal investigator 1 Ionis Pharmaceuticals, Inc. $3,469.02 08/06/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
IS354CS9 No dispute reported 06/30/2026 1246786044
Principal investigator 1 Ionis Pharmaceuticals, Inc. $300.00 07/10/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
IS354CS9 No dispute reported 06/30/2026 1246785187
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,500.00 07/10/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
IS354CS9 No dispute reported 06/30/2026 1246785191
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $9,375.30 06/30/2025 Non-covered Recipient Entity
Lundquist Inst For Biomed At Harbor-ucla Medical
A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LV No dispute reported 06/30/2026 1225412308
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,520.00 05/08/2025 Non-covered Recipient Entity
Lundquist Inst For Biomed At Harbor-ucla Medical
A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LV No dispute reported 06/30/2026 1225412712
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $344.00 04/30/2025 Non-covered Recipient Entity
Lundquist Inst For Biomed At Harbor-ucla Medical
BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fracti No dispute reported 06/30/2026 1225403743
Principal investigator 1 Amgen Inc. $36,550.00 04/24/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR UCLA MEDICAL CENTER
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke No dispute reported 06/30/2026 1246643704
Recipient Amgen Inc. $2,909.45 03/31/2025 Covered Recipient Physician P4 Global Vesalius Real No dispute reported 06/30/2026 1246637206
Principal investigator 1 Novo Nordisk AS $9,812.39 03/31/2025 Non-covered Recipient Entity
THE LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION
EX9924-4473 No dispute reported 06/30/2026 1213814680
Principal investigator 1 Cleerly, Inc. $119.49 03/24/2025 Non-covered Recipient Entity
The Lunquist Institute
Confirm2 No dispute reported 06/30/2026 1241147438
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,152.60 03/24/2025 Non-covered Recipient Entity
HARBOR - UCLA MEDICAL CENTER
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190308160
Principal investigator 1 Novartis Pharmaceuticals Corporation $58,570.99 03/12/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE BIOMED AT HARBOR
A multi-center, randomized, double-blind, placebo-controlled, parallel-group Phase IIIb study evaluating the effect of inclisiran on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diag No dispute reported 06/30/2026 1190305617
Principal investigator 1 Novartis Pharmaceuticals Corporation $25,434.78 02/27/2025 Non-covered Recipient Entity
THE LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190301891
Principal investigator 1 Novo Nordisk AS $1,700.00 02/21/2025 Non-covered Recipient Entity
THE LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION
EX9924-4473 No dispute reported 06/30/2026 1213744553
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,578.50 02/05/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR UCLA
REALIZE-K Phase IV, randomized, double-blind, placebo-controlled, parallel-group trial evaluating Sodium Zirconium Cyclosilicate (SZC) for the management of hyperkalemia in patients with symptomatic heart failure with reduced ejection fraction, chronic kidney disease and receiving spironolactone No dispute reported 06/30/2026 1185552739
Principal investigator 1 Amgen Inc. $28,026.40 01/30/2025 Non-covered Recipient Entity
HARBOR UNIVERSITY OF CALIFORNIA LOS ANGELES MEDICAL CENTER
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke No dispute reported 06/30/2026 1246642048
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,748.20 01/30/2025 Non-covered Recipient Entity
THE LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190301889
Principal investigator 1 Novartis Pharmaceuticals Corporation $27,032.00 01/30/2025 Non-covered Recipient Entity
THE LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION
A multi-center, randomized, double-blind, placebo-controlled, parallel-group Phase IIIb study evaluating the effect of inclisiran on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diag No dispute reported 06/30/2026 1190301893
Recipient Novartis Pharma AG $4,200.00 01/28/2025 Covered Recipient Physician CKJX839D12303 No dispute reported 06/30/2026 1248109841
Principal investigator 1 Novartis Pharmaceuticals Corporation $101,683.95 01/27/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA AT LOS ANGELES
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190302551
Principal investigator 1 Novartis Pharmaceuticals Corporation $409,869.60 01/06/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE BIOMED AT HARBOR
Imaging Long/term study of Inclisiran on Atherosclerotic Disease (ILIAD) Trial No dispute reported 06/30/2026 1190305615
Recipient Canon Medical Informatics, Inc. $10,000.00 01/01/2025 Covered Recipient Physician Cardiac Analysis No dispute reported 06/30/2026 1254963070